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Abstract
The Global Initiative for Chronic Obstructive Lung Disease (GOLD), an international committee of experts, has recently
published its updated report on diagnosis and management of Chronic Obstructive Pulmonary Disease (COPD).
Compared to the previous version, this documents has been an extensively revised: the definition has been simplified,
highlighting the importance of respiratory symptoms, and disease development is further discussed, including new
insights on lung development. Spirometry is still required for the diagnosis, and it is described as fundamental tool for
evaluating prognosis, disease progression, and non-pharmacologic treatment. However, differently from the previous
version, spirometry is no longer included in the ABCD tool (ie, a practical tool proposed to assess COPD symptom
burden and guide pharmacologic treatment), which is now centered exclusively on respiratory symptoms and
history of exacerbation. Subsequently, pharmacologic treatment has been shifted towards a more personalized
approach, reflecting the ongoing process toward a comprehensive, patient-tailored management.
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Introduction
The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) is an international committee of experts who
periodically update the knowledge on the diagnosis and
management of chronic obstructive pulmonary disease
(COPD), based on an extensive scientific discussion
and published evidence in the literature [1].
Since 2001 the document has been published every year
reporting recommendations to be shared and implemented
in different countries. Every 5-year the document is
extensively revised so representing a formal new update
by GOLD committee on the disease.
Review
This year 2017, the GOLD initiative published the 5-year
update on the diagnosis and management of COPD. This
document encloses new insights on the disease, specifically
on diagnosis, classification and therapeutic approaches,
which represent substantial changes from previous
publications (Table 1).
Disease definition
The definition of COPD now reads as “a common, prevent-
able and treatable disease that is characterized by persistent
respiratory symptoms and airflow limitation that is due to
airway and/or alveolar abnormalities usually caused by sig-
nificant exposure to noxious particles or gases”. Compared
to the previous definition, it introduces the concept of per-
sistent symptoms, while discarding the putative pathogenic
mechanism (i.e., enhanced inflammatory response); exacer-
bation, progression, and comorbidities are similarly not
included in the revised definition of the disease. Overall,
the new definition is essentially a description of lung and
airways abnormalities following exposure to noxious stimuli
and leading to symptoms.
The addition of a clear reference to persistent respiratory
symptoms is the first novelty of this report, and focuses on
the patient and on the clinical presentation. In this regard,
the correct interpretation of chronic symptoms has always
been a much debated topic: for example, chronic dyspnea,
cough, and sputum production have been reported in
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smokers who do not have documented airflow obstruction
[2]. These symptomatic smokers exhibit higher rates of
respiratory exacerbations, lower exercise capacity, worse
quality of life, and often receive bronchodilators, even with-
out a confirmed diagnosis of COPD [3, 4]. Moreover, these
subjects may have slightly altered lung function (e.g., lower
lung function, greater airway thickening or emphysema),
compared to smokers without symptoms [4, 5]. Thus, the
GOLD 2017 recognizes that chronic respiratory symptoms
may be present in the absence of abnormal spirometry,
may be associated with structural lung alteration, and may
precede the development of airflow limitation [6]. However,
available data are insufficient to perform a radical change in
the definition of COPD, to include these subjects and align
them to individuals with documented airflow obstruction.
Moreover, albeit recognizing the limits of spirometry, this
test is central in the detection of airflow limitation, and thus
remains the cornerstone of the diagnosis of COPD, as in
the previous documents [6].
Disease development
The section on factors that influence disease develop-
ment and progression has been largely updated, discuss-
ing the origin of COPD, relating it to interactions with
host factors and environmental exposures. Cigarette
smoking remains the most well studied risk factor for
the so-called self-inflicted disease in the 2017 document.
However, not all smokers will develop COPD, while
airflow limitation may develop in non-smokers [6], thus
the putative pathogenic mechanisms have been investigated
further. For example, poor lung growth is listed among
the important risk factors for COPD, as any element
that affects lung growth during gestation and childhood. It
seems that prenatal and early-life insults (e.g., maternal
smoking during pregnancy, and lung infection in early
childhood) may influence the correct development of the
organs, including the lungs, and their capacity for repair
[7, 8]. Therefore, lung function has different trajectories of
development and different trajectories of decline during
the entire lifespan [9].
Exposure to particles such as occupational exposures,
indoor air pollution from biomass cooking and heating
in poorly ventilated dwellings, low socioeconomic status,
and lung disorders (eg, airway hyper-responsiveness, chronic
bronchitis, infections) are other cited environmental risk fac-
tors for the development and the progression of COPD [6].
The final pathogenic mechanism still recognizes an
altered chronic inflammatory response in the lung, which
induces parenchymal tissue destruction, altered lung re-
pair, and abnormal defense mechanisms, ultimately
resulting in emphysema and small airway fibrosis [10, 11].
Moreover, systemic inflammation may be present, and
could play a role in the development of multiple comorbid
conditions. The mechanisms for this amplified inflamma-
tory response are not completely understood, as disease
development and progression derives from complex and
lifelong interactions between genetic background, genes
expression, environmental exposures, and risk factors.
Table 1 Summary of recommendations in new GOLD document comparing to old ones
Topic Previous Documents 2017 Document
Definition of COPD “COPD, a common preventable and treatable disease,
is characterized by persistent airflow limitation that is
usually progressive and associated with an enhanced
chronic inflammatory response in the airways and the
lung to noxious particles or gases. Exacerbations and
comorbidities contribute to the overall severity in
individual patients”
Revised and simplified, to include the impact of respiratory
symptoms and the role of lung tissue and airway abnormalities
in the development of COPD
Disease development
and progression
Genes, age, gender, low growth, exposure to particles,
socioeconomic status, bronchial hyper-reactivity and
infections are discussed
COPD development is further discussed, including new insights
on lung development and on interactions of host factors and
environmental exposures
COPD assessment tool Based on the ABCD assessment tool, considering severity
of airflow obstruction (FEV1), severity of symptoms (CAT,
mMRC questionnaire) and history of exacerbations (>1)
ABCD assessment tool has been modified to utilize only
respiratory symptoms and history of exacerbation
Role of spirometry Provides fundamental information for the diagnosis,
prognosis, the assessment of the disease, and the
pharmacologic and non-pharmacologic management
The role has been revised. It is now fundamental in the diagnosis,
prognosis, and discussion around non-pharmacologic treatment
such as surgery
Non-pharmacologic
therapies
Rehabilitation, oxygen therapy, ventilatory support,
surgical treatment and end-of-life care are discussed
Evidence has been added on evaluation of inhaler technique,
self-management, integrated care, and bronchoscopic
interventions
Pharmacologic
treatment
Treatment of stable COPD is individualized according
to ABCD categories, with different options for each
category
Shifts towards a more personalized approach (revised ABCD
assessment tool, escalation and de-escalation strategies)
Comorbidities Included in the definition of the disease, and discussed
in a specific chapter
The complex issues of multimorbidity and polypharmacy have
been added and discussed
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Diagnosis and assessment
The chapter on diagnosis of COPD presents a major
change, i.e., the revision of the ABCD assessment tool.
In the new document, the tool has been modified to
utilize respiratory symptoms and exacerbations to assign
categories (ABCD), but separating the spirometric measure
from these evaluations. This change is another example of
the ongoing process toward a patient-tailored management.
At first, COPD was classified into four grades (mild,
moderate, severe and very severe) according to post-
bronchodilator FEV1: lung function drove allocation of
pharmacologic therapy to prevent and control symp-
toms and exacerbations [12]. Later, in 2011, the assess-
ment by categories was introduced: this tool evaluated
symptoms, history of exacerbations, and the severity of
airflow limitation. Patients were thus split into four categor-
ies (ie, ABCD), according to their symptoms, lung impair-
ment and future risk of exacerbations. The pharmacologic
and non-pharmacologic therapies matched this assessment
[13]. However, the staging system in COPD remained a
matter of debate, and subsequent analysis did not prove
either scheme to be able of predicting mortality at the indi-
vidual level. Moreover, the GOLD 2011 re-classification
shifted the overall COPD severity distribution to more
severe categories, but without clearly documented benefits
on outcomes [14].
Furthermore, the ABCD classification based on airflow
severity and patient-reported outcome caused some
confusion: for example, group C (high risk without signifi-
cant symptoms) was rather uncommon, and had similar
exacerbation frequency than group B (high symptoms but
low risk); on the other hand, group D (which included sub-
jects with severe airflow limitation alone, or with history of
frequent exacerbations alone, or with both risk factors) had
significant heterogeneity in exacerbation rate [15, 16].
Therefore, in the current update, the ABCD categories
are derived exclusively from symptoms and history of
exacerbations. The separation of airflow obstruction
from clinical parameters was made to clarify what was
being evaluated and ranked by severity. Moreover, this
scheme was proposed to facilitate treatment recommenda-
tions based on individual parameters. Various recommen-
dations, especially pharmacologic treatments, are based on
ABCD categories, and thus derived exclusively from
patient’s symptom experiences and exacerbation history.
The revised assessment acknowledges, on the one hand,
the additional and important prognostic information
derived both from dyspnea and exacerbation and, on the
other, the limitations of FEV1 in guiding the choice of
therapy [17–19]. Indeed, significant heterogeneity in
symptoms and quality of life has been reported in patients
with similar degree of airflow obstruction, and daily or
weekly variation in dyspnea was not related to FEV1 [20].
As the primary goal of medications in COPD is to reduce
symptoms, frequency and severity of exacerbations, and
improve health status, it seems clear why a clinical assess-
ment tool has been suggested.
Therefore, few therapeutic decisions are now based
on spirometry, such as considering an alternative diag-
nosis when symptoms are disproportionate to the degree
of airflow obstruction, or evaluating additional non-
pharmacological and interventional procedures [1].
Notwithstanding, FEV1 is an important prognostic
marker, and it has been significantly linked to negative
outcomes such as higher mortality [21, 22], and in-
creased risk of lung cancer [23]. Similarly, the rate of
FEV1 decline during follow-up may be an important
and clinically relevant indicator of the rate and type of
disease progression [24, 25].
Furthermore, the ABCD assessment tool has various
limitations: this tool has been proposed to structure and
standardize the assessment of symptom burden and to
create treatment plans in COPD patients [6], but has
limited value in predicting mortality: for example, the
2011-ABCD GOLD predicted global mortality with an
area under the curve of ROC of 0.68 in one report [26],
and 0.52 in another one [27]. Moreover, symptom
assessment is based either on the mMRC or the CAT
questionnaire, but these two tests are not equivalent,
may even be discordant in the same patient and, thus,
are not interchangeable [28]. Further, data have been
provided to support the philosophy beyond the new
2017 ABCD assessment tool, but obviously there is no
evidence yet on its real efficacy in guiding therapeutic
decision. Consequently, data on this new approach to
COPD are eagerly awaited.
Disease management
The chapter on management presents some important
updates in the present document: for example, the evalu-
ation of the inhaler technique is now recommended. This
recommendation acknowledges the evidence suggesting
that the inhalation technique of the COPD patient may
not be always appropriate, nor the compliance with treat-
ment be optimal [29]. According to recent data on inhaler
technique errors, it seems that only 6% of the patients
have an optimal skill and adherence with inhalers [30].
Thus, it is necessary that clinicians recognize the different
devices and techniques, and suggest the most appropriate
for each individual patient [31].
Additionally, the patient with COPD is asked to play
an active role in the whole management of the disease,
through self-management, participation in rehabilitation
programs, and discussion over end of life and prolonged
care (i.e., hospice). For example, published evidence
suggests that physical activity is decreased in COPD
patients, leading to a downward spiral of inactivity,
linked to reduced health status, and increased rates of
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hospitalization and mortality [32]. On the contrary,
COPD subjects who perform some level of regular
physical activity have a significantly lower risk of mortality
[33]. Thus, self-management interventions move beyond
the sole education of the patient, and usually include smok-
ing cessation, self-recognition of exacerbations, coping with
breathlessness, and advice on physical activity, diet and
medications. As a consequence, dyspnea, quality of life and
clinical outcomes (e.g., admissions) may improve, although
data are not fully consistent, due to substantial heterogen-
eity among interventions and study populations [34–36].
Based on the previously discussed revisions on COPD
patients’ classification, the 2017 document presents import-
ant updates in the therapeutic indications and the pharma-
cological treatment algorithms.
Overall, it is most recommended that drugs should be
personalized, according to the individual’s characteristics:
symptoms and future risk of exacerbations, but not FEV1,
are clinical key elements that guide the pharmacological
management in stable COPD.
Moreover, and for the first time, the new algorithms of
treatment include strategies for escalation and de-escalation
of therapies based on symptoms and exacerbations. In par-
ticular, increasing symptoms and/or exacerbation number
may warrant additional medications, i.e., combined bron-
chodilators (LABA and LAMA) or ICS to reduce future
risks. Published evidence evaluating the effects of ICS with-
drawal (de-escalation) is not consistent, although the out-
come differences between patients continuing medication
and patients who do not are not significant [37]. A trial on
over 2000 patients with severe COPD receiving triple ther-
apy demonstrated that ICS withdrawal was non-inferior to
continued use of glucocorticoid, with respect to exacerba-
tions, dyspnea and health status, although a significant
reduction in FEV1 (−38 ml) was observed [38]. A post-hoc
analysis of the same study population suggested that
patients with higher exacerbation rate had higher eosino-
phil counts: authors concluded that eosinophil counts ≥ 4%
(or 300 cell/μL) may identify a subgroup of severe COPD at
higher exacerbation risk following withdrawal [39].
Therefore, blood eosinophil level might identify those
patients with distinct characteristics (e.g., older, associ-
ated asthma, higher readmission rates) and different re-
sponse to ICS [11, 40, 41].
Overall, the role and indication of ICS in COPD patients
is revised in the new document. Group B patients should
be started on single bronchodilator, either LAMA or
LABA, while the LAMA/LABA combination may be
started soon in the more symptomatic patients. Accordingly,
a recent exploratory analysis, showed that the LAMA/LABA
combination was superior to placebo and monotherapy in
symptomatic patients with low exacerbation risk [42]. ICS in
not recommended alone nor as an addition to either LAMA
or LABA in group B.
Group C patients should be prescribed a LAMA as the
initial therapy (ICS/LABA combination or LAMA were the
first choice in 2011 document). If exacerbations persist,
combination therapy is then indicated, preferably LABA/
LAMA as inhaled corticosteroids may increase the risk of
pneumonia [43, 44].
Similarly, patients in group D should be started on
LAMA or LAMA/LABA according to the revised docu-
ment. The main source for these new indication was the
FLAME trial [45]: this was a large, randomized, double-
blind, double-dummy, non-inferiority trial, where 3362
symptomatic COPD patients with a history of exacerba-
tions were randomized to LAMA/LABA (indacaterol–
glycopyrronium) or ICS/LABA (salmeterol–fluticasone).
The primary outcome was the annual rate of exacerbations,
which was significantly lower in the group of patients
treated with LAMA/LABA than with ICS/LABA. Further,
the LAMA/LABA group had a longer time to first ex-
acerbation, and a lower annual rate of moderate/severe
exacerbations. The overall incidence of adverse events
was similar, although the incidence of pneumonia was
significantly higher in the ICS/LABA group. Thus, ICS
performs as an anti-inflammatory agent in the COPD
population, and in the 2017 GOLD document it is indi-
cated in combination with LABA in those patients with
moderate to very severe COPD and repeated exacerba-
tions, or showing poor response to bronchodilators [1].
Notwithstanding, as published evidence is conflicting,
the scientific debate on the definitive role of ICS in
patients with stable COPD is still open. Recently, a large,
real-life, prospective, randomized trial, the SALFORD
study, has been conducted in 75 general practitioners in
UK to evaluate usual clinical practice in the manage-
ment of this disease: 2802 COPD patients with a history
of exacerbations, and taking regular maintenance inhaler
therapy, were randomized to either ICS/LABA (fluticasone
furoate–vilanterol) or continuation of usual care as deter-
mined by the general practitioner. The primary outcome
was the mean annual rate of moderate or severe exacerba-
tions, and exacerbation rate was 8.4% lower with ICS/
LABA, with no difference in the time to first exacerbation,
nor in the rate of severe exacerbations and serious adverse
events, including pneumonia [46]. Likewise, an earlier ob-
servational study evaluating the real-life practice in Italy,
has documented a benefit on survival when adding ICS to
LABA in patients experiencing exacerbations: more specif-
ically, 18,615 patients discharged for an acute exacerbation
of COPD were identified from hospital records, and classi-
fied as new users of LABA alone or new users of ICS and
LABA. Crude mortality rate was higher in the LABA alone
group, and also the adjusted hazard ratio favored combin-
ation therapy [47]. Additionally, a multicenter, randomized,
double-blind, controlled trial of LABA (vilanterol) versus
ICS/LABA (fluticasone furoate-vilanterol) in 1620 COPD
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patients with a history of exacerbation and current COPD
symptoms, reported a statistically significant adjusted mean
treatment difference in FEV1 from baseline, in favor of the
ICS/LABA combination therapy [48].
Moving to non-pharmacologic treatments, for the first
time the GOLD document introduces intervention bron-
choscopy with valves or coils as an option in selected pa-
tients with emphysema and hyperinflation. Diverse factors
need to be considered when choosing bronchoscopic lung
reduction versus surgical resection (lung volume reduction
surgery), including the extent and pattern of emphysema
identified on HRCT, the presence of interlobar collateral
ventilation, patient and provider preferences and local
expertise. For example, in patients with fissure integrity
or lack of interlobar collateral ventilation based on physio-
logic assessment, endobronchial valve or lung coil treatment
may be evaluated [49]. Similarly, patients with homogenous
emphysema may be considered for bronchoscopic lung re-
duction [50]. On the contrary, endobronchial valve therapy
is not useful in patients with lack of fissure integrity or if
interlobar collateral ventilation is present. Overall, it seems
that these procedures can improve clinical health outcomes,
although with a non-negligible rate of adverse events [51].
Comorbidities
Finally, the 2017 GOLD document devotes new insights
to comorbidities in its last chapter. COPD is known to
be associated with other concomitant conditions, including
cardiovascular and muscular-skeletal diseases, osteoporosis,
mood disorders, and cancer, evoking multimorbidity as the
most likely clinical figure in these patients [52]. Accord-
ingly, the importance of the active search, diagnosis, and
treatment of any comorbidity associated to COPD is now
recommended [1]. Interestingly, the last section of this
chapter focuses on the issue of multiple drug therapies, in-
dicating that treatments should be kept simple, avoiding
the unbearable polypharmacy that these patients are often
exposed to. Pharmacological treatments should be revised
taking into account evidence of likely benefits and harms
for the individual patient, as well as outcomes important to
the person.
Conclusions
The GOLD 2017 document reports several new insights
into the diagnosis and the management of the patients
with COPD. This seems a step toward achieving a com-
prehensive, personalized and patient-centered approach,
which will probably be the key for treating the complex
patient with COPD.
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